Free Trial
NASDAQ:SMTI

Sanara MedTech (SMTI) Stock Price, News & Analysis

Sanara MedTech logo
$33.68 +2.09 (+6.62%)
(As of 12/20/2024 05:16 PM ET)

About Sanara MedTech Stock (NASDAQ:SMTI)

Key Stats

Today's Range
$31.21
$33.87
50-Day Range
$30.99
$37.70
52-Week Range
$26.00
$43.25
Volume
84,708 shs
Average Volume
21,180 shs
Market Capitalization
$294.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00
Consensus Rating
Buy

Company Overview

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Sanara MedTech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

SMTI MarketRank™: 

Sanara MedTech scored higher than 40% of companies evaluated by MarketBeat, and ranked 693rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sanara MedTech has received no research coverage in the past 90 days.

  • Read more about Sanara MedTech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanara MedTech is -34.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanara MedTech is -34.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sanara MedTech has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.31% of the float of Sanara MedTech has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanara MedTech has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Sanara MedTech has recently decreased by 7.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sanara MedTech does not currently pay a dividend.

  • Dividend Growth

    Sanara MedTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.31% of the float of Sanara MedTech has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanara MedTech has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Sanara MedTech has recently decreased by 7.72%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 8.10% of the stock of Sanara MedTech is held by institutions.

    • Read more about Sanara MedTech's insider trading history.
    Receive SMTI Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

    SMTI Stock News Headlines

    Sanara MedTech to Present at Healthcare Conference
    2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
    Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
    Sanara MedTech Reports Strong Revenue Growth Amid Challenges
    Sanara MedTech reports Q3 EPS (34c) vs (13c) last year
    See More Headlines

    SMTI Stock Analysis - Frequently Asked Questions

    Sanara MedTech's stock was trading at $41.10 at the beginning of 2024. Since then, SMTI stock has decreased by 18.1% and is now trading at $33.68.
    View the best growth stocks for 2024 here
    .

    Sanara MedTech Inc. (NASDAQ:SMTI) issued its earnings results on Tuesday, November, 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.28. The firm earned $21.67 million during the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative trailing twelve-month return on equity of 19.86%.

    Sanara MedTech's top institutional shareholders include Geode Capital Management LLC (1.01%), State Street Corp (0.67%), Janney Montgomery Scott LLC (0.38%) and World Investment Advisors LLC (0.24%). Insiders that own company stock include Zachary B Fleming and Shawn M Bowman.
    View institutional ownership trends
    .

    Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

    Company Calendar

    Last Earnings
    11/12/2024
    Today
    12/22/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Surgical appliances & supplies
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:SMTI
    Fax
    N/A
    Employees
    60
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $44.00
    High Stock Price Target
    $44.00
    Low Stock Price Target
    $44.00
    Potential Upside/Downside
    +30.6%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Net Income
    $-4,300,000.00
    Pretax Margin
    -10.86%

    Debt

    Sales & Book Value

    Annual Sales
    $78.06 million
    Book Value
    $5.22 per share

    Miscellaneous

    Free Float
    4,012,000
    Market Cap
    $294.40 million
    Optionable
    Not Optionable
    Beta
    1.57
    (Almost)  Everything You Need To Know About The EV Market Cover

    Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

    Get This Free Report

    This page (NASDAQ:SMTI) was last updated on 12/22/2024 by MarketBeat.com Staff
    From Our Partners